Novartis ' Sandoz Is Back In The Insulin Biosims Market. Can It Succeed?

Back in December 2018, the Sandoz division of Swiss pharmaceutical giant Novartis announced (see the full announcementHERE) " Sandoz enters into commercialization and supply agreement for insulin biosimilars " . It also revealed that Sandoz had entered a " commercialization and supply agreement with Gan& Lee " which it added was " a leading insulin supplier headquartered in China with more than 20 years ' experience in insulins and production capacity with attractive cost of goods sold (COGS) structures " .Few Americans have ever heard of Gan& Lee, although this year, at the American Diabetes Association ' s 82nd Scientific Sessions in New Orleans, Gan& Lee had its first-ever exhibit in the vendor hall at the event (which was a hybrid event being help both in-person, as well as virtually, hence the exhibit hall wasn ' t as busy as others are.Gan& Lee (now has an English language Twitter feed at@GanLee_ if you ' re inclined to follow the feed) and the company also set up an exhibit of its own at this year ' s ADA Scientific Sessions. It Tweeted " It ' s been three years since Gan& Lee exhibited at ADA tradeshow which was held in San Francisco in 2019. " However, that was a tradeshow, not the ADA Scientific Sessions. Several pics from this year ' s ADA are found below.        The Sandoz/Gan& Lee announcement added that Sandoz intended to commercialize biosimilar versions of insulins " for the European Union (EU), U...
Source: Scott's Web Log - Category: Endocrinology Tags: insulin analogs 2022 Biosimilar biosimilars generics insulin analogues Novartis Sandoz Source Type: blogs